Latest News

Product acquisition

Concordia/AMCo announced today that they have entered into an agreement to acquire the global rights to four generic products, for the treatment of anemia, depression and urticaria, for a £21 million initial payment and up to £7 million in subsequent earn-out payments that would be payable in the first quarter of 2017 if certain performance and supply targets are achieved.  They paid a revenue multiple of 2.6 times for this acquisition and intend to pay with cash on hand. The transaction is expected to close on or about May 31, 2016.